Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

News Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-22 pm EDT 		5-day change 1st Jan Change
49.14 USD +0.43% Intraday chart for Bristol-Myers Squibb Company +1.30% -4.23%
09:21am Novartis raises targets for 2024 CF
Apr. 22 Alexandria Real Estate's Q1 FFO rises on stronger occupancy rates RE

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Novartis raises targets for 2024
CF
Alexandria Real Estate's Q1 FFO rises on stronger occupancy rates
RE
Bristol-Myers Squibb Signs $380 Million Deal With Cellares to Manufacture CAR T Cell Therapies
MT
Bristol Myers signs $380 mln CAR-T therapies supply deal with Cellares
RE
Bristol Myers signs supply agreement with Cellares
CF
Bristol Myers Squibb and Cellares reach $380 mln supply deal for CAR-T therapies
RE
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
BU
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
BU
Bristol Myers Squibb and Cellares Announce Worldwide Capacity Reservation and Supply Agreement for Manufacture of CAR T Cell Therapies
CI
Cantor Fitzgerald Adjusts Bristol-Myers Squibb's Price Target to $52 From $55, Maintains Neutral Rating
MT
US FDA mandates label updates on CAR-T cancer therapies
RE
Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating
MT
Pathios Therapeutics Limited announced a financing transaction
CI
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest
AQ
TORL BioTherapeutics LLC announced that it has received $158.3 million in funding from a group of investors
CI
Asher Biotherapeutics, Inc. announced that it has received $55 million in funding from a group of investors
CI
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb Company to $55 From $57, Outperform Rating Kept
MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb to $55 From $57, Maintains Outperform Rating
MT
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
PR
Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BMY Stock
  4. News Bristol-Myers Squibb Company